This supplement is intended to focus on ligand-receptor interactions and drug design. Biochemistry of ligand binding, experimental drug design and computational drug design are included within the supplement's scope.
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At the discretion of the guest editors other articles on other relevant topics within the scope of the supplement may be included. ). Dysfunction of these signaling pathways is responsible for various human diseases like cancer, diabetes and so on. Receptor signaling can be improperly overactivated (e.g. BCR-ABL oncogene in chronic myeloid leukemia), or impaired as a result of either lacking the ligand or mutations in the receptor complex (e.g. type I and II diabetes). Therefore, receptors are the targets of a lot of pharmaceutical agents. The study of receptors and their ligands is critical for elucidating the physiological and pathological processes they are involved in. By understanding the underlying mechanisms, we can find better ways to improve human health.
Supplement Aims and Scope

LIGAND-RECEPTOR INTERACTIONS AND DRUG DESIGN
In this issue, three studies about ligand-receptor interaction are presented. Various aspects of the drug discovery dynamics are covered: how to prepare ligands in vitro, how to study functional receptors in vivo and how we can rationally design drugs based on what we know about ligand-receptor interactions. All of them are aimed for clinical applications.
In Wu et al, a novel way for preparing a promising drug candidate Olesoxime (cholest-4-en-3-one) is described. Olesoxime has been reported to bind two proteins of the mitochondrial permeability transition pore: the voltage-dependent anion channel and the peripheral benzodiazepine receptor. 1 Wu et al set out to prepare this ligand in a defined, cell extract-free procedure and successfully acquired a product with a purity of 99.78%. With its analgesic and neuroprotective effect, 2 olesoxime is a promising compound for treating multiple neuropathies: amyotrophic lateral sclerosis (ALS), 3 Huntington disease, 4 Parkinson disease, 5 and even autism. 6 Although a recent Phase II/III with ALS patients did not show conclusive benefits, 7 other clinical trials with muscular dystrophy patients have been gaining momentum. 8 In Jin's study, the molecular mechanism of an important phenomenon, cold pain, is probed with receptor/ligand interaction. Most of us are familiar with the noxious headache when our dental pulp is exposed to cold drink/food. It is already known that transient receptor potential (TRP) channels are little antennas responsible for our sensations to temperature, pressure, taste, vision and pain. 9 The cold pain pathway is less understood than other sensations but generally thought to be mediated by TRP channels. 10 While only in vitro or behavioral approaches have been used previously, 10 Dr. Jin took a functional approach to tackle this problem, modifying the status of TRP channels with a broad spectrum TRP channel blocker to show that this can suppress the response of nociceptive neurons to cold stimulation in dental pulp.
Moreover, this study showed for the first time that in vivo electrophysiological technique can be used as an alternative and effective approach for evaluating the effects of some drugs in animal models. It could open up new therapeutic routes for an age old problem.
Finally, an excellent review by Dr. Chen describes carbamoylated EPO, a derivative of natural Erythropoietin (EPO). EPO is widely known for its role in red blood cell production (erythropoiesis). It is medically used in various anemia conditions and, unfortunately, consumed by some athletes illegally for performance enhancing. In addition, EPO also has a non-classical role in neuro-protection. The dual roles of EPO are mediated by different receptor complexes. 11 This presents an opportunity to design EPO derivatives that are neuro-protective but not erythropoietic in order to avoid side effects resulting from high dose EPO usage, like thrombosis. 12 Carbamoylated EPO is one of such derivatives. This is an elegant case of rational drug design at its finest using ligand receptor biology.
In summary, we hope this issue on Ligand-Receptor Interactions and Drug Design gives you more thoughts on the diversity and great potential of this topic. More exciting findings are on the way. she can be contacted at jruisong@umich.edu.
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